Blood Sugar News and Research

RSS

Blood sugar concentration, or glucose level, refers to the amount of glucose present in the blood of a human or animal. Normally, in mammals the blood glucose level is maintained at a reference range between about 3.6 and 5.8 mM (mmol/l). It is tightly regulated as a part of metabolic homeostasis.

'Pre-vascularization' of device prior to implantation sustains circulation and suppresses scar formation

By creating a unique system of blood vessels that is engineered to interact with the tissue surrounding an implanted device, the longevity and function of these devices may be better preserved, according to a study led by researchers in the University of Louisville/ Jewish Hospital's Cardiovascular Innovation Institute (CII).

24 Aug 2010

Researchers find medication for diabetes, smoking cessation

The script for two research teams inducted today into the American Chemical Society (ACS) scientific "hall of fame" the ACS Heroes of Chemistry is a tale of two pills. One team invented a medication that helps people with diabetes control their blood sugar levels. The second team invented a medicine that helps people stop smoking, an addiction that experts regard as today's single greatest preventable cause of death worldwide.

23 Aug 2010

JDRF announces key step on road to artificial pancreas

JDRF announced today another important step on the road to the development of an artificial pancreas - an automated system to better manage the blood sugar of people with type 1 diabetes - with the establishment of a research program to speed the development of faster-acting insulin.

17 Aug 2010

$Study finds first clue that links childhood obesity to skeletal fractures$

Study finds first clue that links childhood obesity to skeletal fractures

Children at risk for diabetes before they reach puberty also appear to be at risk for weak bones, Medical College of Georgia researchers report.

16 Aug 2010

Researchers examine differences in eating habits of African Americans

7 Aug 2010

Survey reveals need for nutrition education among African Americans for disease prevention, management

Researchers looking for differences in eating habits of African Americans based on whether or not they had Type 2 diabetes uncovered an unexpected result: No matter what the blood sugar level was, the dietary intakes were pretty much the same.African Americans are 1.8 times more likely to develop Type 2 diabetes and 1.4 times more likely to be obese than are non-Hispanic whites, according to federal health agencies. Obesity is a leading risk factor for development of diabetes, a condition that results when the body cannot properly use insulin to transfer sugar from the blood to muscle and fat cells that use glucose for energy.

6 Aug 2010

Merck's two pivotal boceprevir Phase III registration studies for chronic HCV meet primary endpoint

Merck reported that two pivotal Phase III registration studies for boceprevir, its investigational oral hepatitis C protease inhibitor, have been completed and met the primary endpoints: in both studies in patients with chronic hepatitis C virus (HCV) genotype 1 infection, the addition of boceprevir to treatment with PEGINTRON® and REBETOL® significantly increased the number of patients who achieved sustained virologic response, compared to control groups that received Peg/riba plus placebo.

5 Aug 2010

Study explores benefits, risks of aggressive blood sugar control in hemodialysis patients

Aggressive blood sugar control does not improve survival in diabetic patients with kidney failure, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society Nephrology. The results suggest that physicians should individualize blood sugar targets for these patients and not rely on recommendations based on studies in the general population.

30 Jul 2010

Human insulin-producing beta cell replication sustained with single stimulatory molecule: Study

With a single stimulatory molecule, human insulin-producing beta cell replication can be sustained for at least four weeks in a mouse model of diabetes, according to researchers at the University of Pittsburgh School of Medicine in Diabetes, a journal of the American Diabetes Association.

28 Jul 2010

Merck signs non-exclusive license agreement with LabCorp for commercialization of genetic test

Merck announced a non-exclusive license agreement with Laboratory Corporation of America Holdings for the commercialization of a genetic test that may help predict the response of patients with Hepatitis C virus infection to peginterferon alpha-based therapy.

28 Jul 2010

New drug for type 2 diabetes, Effect of insulin on bones

In a groundbreaking finding, a new medicine Galvus (vildagliptin) has been created for people with type 2 diabetes that would lower blood glucose levels without the side effects of other medications.

26 Jul 2010

Mismanagement of diabetes leads to fatal accident

One of the worst case scenarios that can happen to a diabetic is if he or she falls into a hypoglycemic coma. This is caused by a severe deficiency in glucose levels found in the blood which causes the brain to seek other energy sources at the same time shutting down other important body functions. If treatment is delayed or neglected by the diabetic person, such a coma can cause not only loss of consciousness but also irreversible brain damage and death.

26 Jul 2010

Inhibiting fatty acid synthase can reduce atherosclerosis: Study

Scientists at Washington University School of Medicine in St. Louis have found a way to significantly reduce atherosclerosis in mice that does not involve lowering cholesterol levels or eliminating other obesity-related problems.

26 Jul 2010

Insulin action may provide link between bone health, metabolic disease: Study

A new study by Johns Hopkins researchers has found that insulin, the sugar-regulating hormone, is required for normal bone development and that it may provide a link between bone health and metabolic disease, such as diabetes.

23 Jul 2010

Osteocalcin hormone can regulate glucose levels: Research

Researchers led by Columbia University Medical Center have discovered that the skeleton plays an important role in regulating blood sugar and have further illuminated how bone controls this process. The finding, published in Cell, is important because it may lead to more targeted drugs for type 2 diabetes.

23 Jul 2010

Genomics researchers study role of protein in metabolic disorders, heart disease

Studying a protein already known to play an important role in type 2 diabetes and cancer, genomics researchers have discovered that it may have an even broader role in disease, particularly in other metabolic disorders and heart disease. In finding unsuspected links to other disease-related genes, the scientists may have identified future targets for drug treatments.

22 Jul 2010

TCF7L2 protein may play important role in heart disease, other metabolic disorders: Researchers

22 Jul 2010

Study identifies treatment strategies that can slow progression of eye disease associated with diabetes

The VA Maryland Health Care System participated in a landmark national study of more than 10,251 high-risk diabetic adults across the nation, testing if three complementary treatment strategies can reduce the high rate of heart disease and stroke associated with type 2 diabetes and if these treatment strategies can also slow the progression of eye disease associated with diabetes, the leading cause of blindness in working-age Americans.

22 Jul 2010

Fero Industries provides comments concerning FDA advisory panel recommendation on diabetes drug Avandia

Fero Industries, Inc. is pleased to provide these comments regarding the recent Food and Drug Administration advisory panel recommendation concerning the GlaxoSmithKline PLC diabetes drug Avandia. The FDA advisory panel has recommended that the agency keep diabetes drug Avandia on the U.S. market despite data clearly showing an increased risk of a heart attack and that GSK covered up their own research that first identified the problem.

20 Jul 2010

Abbott presents 48-week PROGRESS study results at 28th International AIDS Conference

Abbott today presented 48-week findings comparing an HIV regimen of its protease inhibitor (PI), Kaletra® (lopinavir/ritonavir), and Merck's integrase inhibitor, Isentress® (raltegravir), to a traditional HIV regimen of Kaletra and the nucleotide/nucleoside reverse transcriptase inhibitors (NRTIs) in Truvada® (tenofovir and emtricitabine) in antiretroviral-naive adult patients. Efficacy data were collected over the first 48 weeks of the 96-week PROGRESS (PROtease/InteGRasE Simplification Study) study.

20 Jul 2010

Blood Sugar News and Research

Further Reading

'Pre-vascularization' of device prior to implantation sustains circulation and suppresses scar formation

Researchers find medication for diabetes, smoking cessation

JDRF announces key step on road to artificial pancreas

Study finds first clue that links childhood obesity to skeletal fractures

Researchers examine differences in eating habits of African Americans

Survey reveals need for nutrition education among African Americans for disease prevention, management

Merck's two pivotal boceprevir Phase III registration studies for chronic HCV meet primary endpoint

Study explores benefits, risks of aggressive blood sugar control in hemodialysis patients

Human insulin-producing beta cell replication sustained with single stimulatory molecule: Study

Merck signs non-exclusive license agreement with LabCorp for commercialization of genetic test

New drug for type 2 diabetes, Effect of insulin on bones

Mismanagement of diabetes leads to fatal accident

Inhibiting fatty acid synthase can reduce atherosclerosis: Study

Insulin action may provide link between bone health, metabolic disease: Study

Osteocalcin hormone can regulate glucose levels: Research

Genomics researchers study role of protein in metabolic disorders, heart disease

TCF7L2 protein may play important role in heart disease, other metabolic disorders: Researchers

Study identifies treatment strategies that can slow progression of eye disease associated with diabetes

Fero Industries provides comments concerning FDA advisory panel recommendation on diabetes drug Avandia

Abbott presents 48-week PROGRESS study results at 28th International AIDS Conference

Industry Focus eBook - Forensics & toxicology (2nd edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News